GWPRF - PaxMedica Begins U.S. Mini IPO Process

Quick Take

PaxMedica (PXMD) has filed to raise $18 million in an IPO of its common stock, according to an S-1 registration statement.

The company is developing various forms of suramin for autism, Fragile X syndrome, African sleeping sickness and other neurodevelopmental indications.

PXMD appears to be thinly capitalized and is performing Phase 2b trials in South Africa for its lead candidate.

I’ll provide a final opinion when we learn more about the IPO from management.

Company & Technology

Woodcliff Lake, New Jersey-based PaxMedica was founded to advance programs based on anti-purinergic therapies

Read more ...